Literature DB >> 9129081

Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals.

Y Han1, J E Cutler.   

Abstract

As previously reported, monoclonal antibody (MAb) B6.1 increases resistance to hematogenous disseminated candidiasis in normal and SCID mice. In this study, MAb B6.1 was examined in a mouse model of neutropenia. The neutropenia was induced for a short period of time by a single dose of the anti-neutrophil antibody, MAb RB6-8C5, or for a protracted period by doses of MAb RB6-8C5 every other day. At low doses (< or = 25 microg/mouse), neutrophils were primarily affected, but at high doses (> or = 50 microg/mouse), lymphocytes were also depleted. Mice given either single or multiple doses of MAb RB6-8C5 were more resistant to experimental hematogenous disseminated candidiasis if they received MAb B6.1 before and after challenge with Candida albicans yeast cells intravenously. These results show the utility of MAb RB6-8C5 for induction of a protracted neutropenia in mice and demonstrate that MAb B6.1 can enhance resistance against candidiasis under neutropenic conditions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9129081     DOI: 10.1086/516455

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

1.  Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularization.

Authors:  Jeremy M Sivak; Allison C Ostriker; Amber Woolfenden; John Demirs; Rosemarie Cepeda; Debby Long; Karen Anderson; Bruce Jaffee
Journal:  J Biol Chem       Date:  2011-11-09       Impact factor: 5.157

2.  Enhanced phagocytosis of Candida species mediated by opsonization with a recombinant human antibody single-chain variable fragment.

Authors:  Melanie Wellington; Joseph M Bliss; Constantine G Haidaris
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

Review 3.  New insights into cellular mechanisms during sepsis.

Authors:  Laszlo M Hoesel; Hongwei Gao; Peter A Ward
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

4.  Hybridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasis.

Authors:  Hong Xin; Jim E Cutler
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

5.  Design of a mimotope-peptide based double epitope vaccine against disseminated candidiasis.

Authors:  Hong Xin; Pati Glee; Abby Adams; Farhan Mohiuddin; Karen Eberle
Journal:  Vaccine       Date:  2019-03-28       Impact factor: 3.641

6.  The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy.

Authors:  Shane D Stephens-Romero; Aron J Mednick; Marta Feldmesser
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

7.  Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies.

Authors:  Y Han; T Kanbe; R Cherniak; J E Cutler
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

Review 8.  Emerging drugs and vaccines for candidemia.

Authors:  Brad Moriyama; Lori A Gordon; Matthew McCarthy; Stacey A Henning; Thomas J Walsh; Scott R Penzak
Journal:  Mycoses       Date:  2014-10-08       Impact factor: 4.377

9.  A 70-kilodalton recombinant heat shock protein of Candida albicans is highly immunogenic and enhances systemic murine candidiasis.

Authors:  C Bromuro; R La Valle; S Sandini; F Urbani; C M Ausiello; L Morelli; C Fé d'Ostiani; L Romani; A Cassone
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

10.  A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection.

Authors:  Y Han; R P Morrison; J E Cutler
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.